Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC
NA Pennell, TJ Lynch Jr - The oncologist, 2009 - academic.oup.com
Multitargeted agents represent the next generation of targeted therapies in solid tumors. The
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
NA Pennell, TJ Lynch Jr - The Oncologist, 2009 - europepmc.org
Multitargeted agents represent the next generation of targeted therapies in solid tumors. The
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC.
NA PENNELL, TJ LYNCH JR - Oncologist, 2009 - search.ebscohost.com
Multitargeted agents represent the next generation of targeted therapies in solid tumors. The
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
NA Pennell, TJ Lynch - The Oncologist, 2009 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Multitargeted agents represent the next
generation of targeted therapies in solid tumors. The benefits of individually targeting the …
generation of targeted therapies in solid tumors. The benefits of individually targeting the …
[PDF][PDF] Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
NA PENNELL, TJ LYNCH JR - The Oncologist, 2009 - researchgate.net
Multitargeted agents represent the next generation of targeted therapies in solid tumors. The
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC
NA Pennell, TJ Lynch Jr - The oncologist, 2009 - pubmed.ncbi.nlm.nih.gov
Multitargeted agents represent the next generation of targeted therapies in solid tumors. The
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
[PDF][PDF] Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
NA PENNELL, TJ LYNCH JR - The Oncologist, 2009 - Citeseer
Multitargeted agents represent the next generation of targeted therapies in solid tumors. The
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
[PDF][PDF] Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
NA Pennell, TJ Lynch Jr - The Oncologist, 2009 - Wiley Online Library
Multitargeted agents represent the next generation of targeted therapies in solid tumors. The
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …
benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) …